226 related articles for article (PubMed ID: 31757299)
21. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.
Steinberg RL; Thomas LJ; Nepple KG
Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259
[TBL] [Abstract][Full Text] [Related]
22. Salvage Therapies for Non-muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Guérin? Predictors and Nomograms.
Faba ÓR; Pisano F; Krajewski W; Breda A; Palou J
Urol Clin North Am; 2020 Feb; 47(1):5-13. PubMed ID: 31757300
[TBL] [Abstract][Full Text] [Related]
23. [Nonmuscle-invasive bladder cancer (NMIBC): when to perform cystectomy?].
Lebret T
Prog Urol; 2008 May; 18 Suppl 5():S111-4. PubMed ID: 18585632
[TBL] [Abstract][Full Text] [Related]
24. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Steinberg RL; Thomas LJ; Brooks N; Mott SL; Vitale A; Crump T; Rao MY; Daniels MJ; Wang J; Nagaraju S; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA
J Urol; 2020 May; 203(5):902-909. PubMed ID: 31821066
[TBL] [Abstract][Full Text] [Related]
25. The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.
Haas CR; Barlow LJ; Badalato GM; DeCastro GJ; Benson MC; McKiernan JM
J Urol; 2016 Jun; 195(6):1704-9. PubMed ID: 26807928
[TBL] [Abstract][Full Text] [Related]
26. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
Prasad SM; Eyre S; Loughlin KR
Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
[TBL] [Abstract][Full Text] [Related]
27. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
Barlow LJ; McKiernan JM; Benson MC
J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
[TBL] [Abstract][Full Text] [Related]
28. Recurrent Bladder Cancer in a Teenage Male.
Peard L; Stark T; Ziada A; Saltzman AF
Urology; 2020 Jul; 141():135-138. PubMed ID: 32333990
[TBL] [Abstract][Full Text] [Related]
29. Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model.
Horinaga M; Fukuyama R; Iida M; Yanaihara H; Nakahira Y; Nonaka S; Deguchi N; Asakura H
Urology; 2010 Nov; 76(5):1267.e1-6. PubMed ID: 21056277
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial.
Di Lorenzo G; Perdonà S; Damiano R; Faiella A; Cantiello F; Pignata S; Ascierto P; Simeone E; De Sio M; Autorino R
Cancer; 2010 Apr; 116(8):1893-900. PubMed ID: 20162706
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder.
Wymer KM; Sharma V; Saigal CS; Chamie K; Litwin MS; Packiam VT; Mossanen M; Pagliaro LC; Borah BJ; Boorjian SA
J Urol; 2021 May; 205(5):1326-1335. PubMed ID: 33347775
[TBL] [Abstract][Full Text] [Related]
32. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
McElree IM; Steinberg RL; Martin AC; Richards J; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA; Packiam VT
J Urol; 2022 Sep; 208(3):589-599. PubMed ID: 35892270
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
[TBL] [Abstract][Full Text] [Related]
34. Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guérin therapy.
Fujita N; Hatakeyama S; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Int J Urol; 2022 Aug; 29(8):867-875. PubMed ID: 35577361
[TBL] [Abstract][Full Text] [Related]
35. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what.
Peyton CC; Chipollini J; Azizi M; Kamat AM; Gilbert SM; Spiess PE
World J Urol; 2019 Oct; 37(10):2017-2029. PubMed ID: 30535583
[TBL] [Abstract][Full Text] [Related]
36. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
37. The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.
Packiam VT; Richards J; Schmautz M; Heidenreich A; Boorjian SA
Curr Opin Urol; 2021 May; 31(3):178-187. PubMed ID: 33742981
[TBL] [Abstract][Full Text] [Related]
38. Clinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guérin Failure.
Nazmifar M; Williams C; Naser-Tavakolian A; Heard J; Rosser C; Theodorescu D; Ahdoot M
J Urol; 2023 Jan; 209(1):32-48. PubMed ID: 36067380
[TBL] [Abstract][Full Text] [Related]
39. New agents for bacillus Calmette-Guérin-refractory bladder cancer.
Ahn JJ; McKiernan JM
Urol Clin North Am; 2013 May; 40(2):219-32. PubMed ID: 23540780
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy.
Bassi P; De Marco V; Tavolini IM; Longo F; Pinto F; Zucchetti M; Crucitta E; Marini L; Dal Moro F
Urol Int; 2005; 75(4):309-13. PubMed ID: 16327296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]